Every material Form 8-K Arcus Biosciences filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Arcus Biosciences reported third-quarter 2024 revenue of $48 million, up from $32 million a year earlier, but its net loss widened to $92 million from $71 million as research and development spending rose to $123 million. The company said its $1.1 billion in cash, cash equivalents and marketable securities should fund operations into mid-2027, and it expects year-end 2024 cash of $950 million to $985 million.
Q3 2024 revenue was $48 million versus $32 million in Q3 2023; nine-month revenue was $232 million versus $86 million.
Q3 2024 net loss was $92 million, or $1.00 per share, compared with $71 million, or $0.94 per share, a year earlier.
R&D expenses were $123 million in Q3 2024 versus $82 million, driven by late-stage clinical trial and headcount costs.
Cash, cash equivalents and marketable securities were $1.1 billion at September 30, 2024, up from $866 million at December 31, 2023.
Arcus Biosciences entered a Loan and Security Agreement with Hercules Capital on August 27, 2024, providing a secured term loan facility of up to $250.0 million. Only $50.0 million was funded at closing, with the rest available under later tranches at the company's option or the lenders' option, and the loans are secured by substantially all company assets.
$50.0 million funded on August 27, 2024; up to $150.0 million more available at the company's option through March 15, 2026, and a further $100.0 million at the lenders' option
Interest at the greater of Prime Rate plus 1.95% or 10.45%; interest-only payments until September 1, 2028; maturity September 1, 2029
Financial covenant requires Qualified Cash of at least 50% of outstanding principal when market capitalization is at or below $1.20 billion, with reductions upon milestones
Arcus Biosciences reported second-quarter 2024 revenue of $39 million, up from $29 million a year earlier, while its net loss widened to $93 million from $75 million as research and development expenses rose to $115 million from $84 million. Cash, cash equivalents and marketable securities totaled $1.0 billion at June 30, 2024, and the company said that balance will fund operations into 2027.
Q2 2024 revenue was $39 million versus $29 million in Q2 2023; six-month revenue was $184 million versus $54 million.
Q2 net loss was $93 million versus $75 million; net loss per share was $1.02 versus $1.04.
R&D expenses were $115 million versus $84 million, driven by higher clinical trial and headcount-related costs for late-stage programs.
Cash and marketable securities were $1.0 billion at June 30, 2024, including $320 million received from Gilead for its January 2024 equity investment.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Arcus Biosciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →